


The Fund aims to maximise long-term total return to investors by investing predominantly in undervalued European equities.
| Name | % Net Assets | 
|---|---|
| Total | 5.2% | 
| Nestle | 4.0% | 
| Novartis | 3.9% | 
| Total | 3.8% | 
| Sanofi-Aventis | 3.7% | 
| Sanofi-Aventis | 3.5% | 
| Vivendi | 3.3% | 
| Bayer | 2.9% | 
| Muenchener Rueck | 2.6% | 
| Repsol | 2.6% | 
| Key | % Net Assets | 
|---|---|
| 5.2% | |
| 4.0% | |
| 3.9% | |
| 3.8% | |
| 83.1% | 
| Date | 07-Dec-2018 | 
|---|---|
| NAV | 16.76p | 
| Currency | GBP | 
| Change | -0.65p | 
| % | -3.75% | 
| YTD change | 16.76p | 
| YTD % | n/a | 
| Fund Inception | 01/02/2008 | 
|---|---|
| Fund Manager | n/a | 
| TER | 0.92 (31-Jan-2014) | 
| Minimum Investment | |
|---|---|
| Initial | n/a | 
| Additional | n/a | 
| Savings | n/a | 
| Charges | |
|---|---|
| Initial | 1.25% | 
| Annual Mang't | 0.75% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| No risk data available. | |
You are here: research